Well-differentiated/dedifferentiated liposarcomas (WD/DDLPS) are among the most common subtypes of soft tissue sarcomas. Conventional systemic chemotherapy has limited efficacy and novel therapeutic strategies are needed to achieve better outcomes for patients. The cyclin-dependent-kinase 4 (CDK4) gene is highly amplified in over 95% of WD/DDLPS, In this study, we explored 
Introduction
The retinoblastoma (RB) tumor suppressor gene plays a critical role in regulating cellular proliferation, and loss of function of the RB protein is commonly found in human malignancies (1, 2) . RB function is regulated by phosphorylation of multiple serine and threonine residues, initiated during the G 1 /S cell cycle transition by cyclin-dependent kinases (CDK) 4 or 6 (3) (4) (5) . These enzymes, in turn, are activated by temporal expression of cyclin D, and inhibited by the CDK inhibitor p16 (6, 7) . Multiple mechanisms for dysregulation of this pathway in cancer have been identified, including mutation or loss of expression of RB (2) , overexpression of cyclin D (8, 9) , loss of p16 (10) , and mutation, genomic amplification, or overexpression of CDK4 (11) .
Over 95% of human well-differentiated/dedifferentiated liposarcomas (WD/DDLPS) exhibit dysregulation of CDK4 through high level amplification of a region of the long arm of chromosome 12 containing this gene (12, 13) .
WD/DDLPS represent one of the most common forms of soft tissue sarcomas (14, 15) . WDLPS is a typically indolent, non-metastasizing disease that can be cured by surgical excision, although local recurrences are common. DDLPS may arise from WDLPS or de novo, and may also be cured by surgical resection, although its rapid growth rate, predilection for retroperitoneal growth, and ability to be locally destructive or metastasize frequently results in recurrences and patient mortality. Clinical benefit from conventional systemic chemotherapy is limited, transient, and often toxic, indicating that newer therapeutic strategies are needed to better treat this disease (16, 17) . CDK4 shRNA or the CDK4/6 inhibitor PD0332991 (19) . A more recent study also reported that the addition of an IGF1R inhibitor to PD0332991 led to greater inhibition of cell cycle progression and cell metabolic activity (20) . However, Detailed biochemical analyses and the preclinical in vivo effects of CDK4/6 inhibitors on liposarcoma xenograft models have not yet been described, and predictive biomarkers for CDK4/6 inhibitor activity are still lacking. Recently, several CDK4/6 inhibitors have entered into clinical development, and an exploratory clinical trial suggested activity against liposarcoma (21) . In this study, we explore the biochemical, antiproliferative, and antimetabolic effects of CDK4 inhibition in more detail than has previously been reported, using siRNA and the novel small molecule CDK4/6 inhibitor NVP-LEE011 (LEE011) in both cell line and patient-derived tumor xenograft models of WD/DDLPS. (24) . Liposarcoma cell lines were characterized by highresolution short tandem repeat (STR) profiling with Promega PowerPlex ®1.2 system at the Molecular Diagnostics Laboratory of Dana-Farber Cancer Institute.
Materials and Methods

Cell Lines and Cell Culture
The cells used for the experiment are passaged for fewer than 6 months after authentication.
Inhibitors and siRNA
The CDK4/6 inhibitor NVP-LEE011 (succinate salt, powder form) (LEE011) (25) . ON-TARGETplus siRNA against RB1 (#J-003296-10, 13), CDK4 (#J-003238-12, 13), and scrambled control were purchased from Dharmacon (Layfayette, CO). Cells were transfected with siRNA at a final concentration of 3.12-6.25 nM with RNAiMAX (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol.
Copy Number Analysis
Gene copy number was determined by probe-based quantitative real-time PCR using StepOnePlus™ real-time PCR system (Applied Biosystems, Foster City, CA). Human male normal genomic DNA was purchased from PE Biosystems (Foster City, CA). Genomic DNA from cell cultures was extracted using the DNeasy blood and tissue kit (Qiagen, Valencia, CA 
Immunoblots
Cells were lysed on ice in lysis buffer containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM EGTA, 10% Glycerol, 1% Triton X-100, 100 mM NaF, 10 mM 
Cell Proliferation Assay
Cells were exposed to various treatments (inhibitor, siRNA or vehicle control) for times as indicated. Cell numbers were determined using a Neubauer haemocytometer.
To determine the half maximal growth inhibitory concentration (GI 50 ) values of LEE011 in liposarcoma cells, cell numbers were counted before treatment (T 0 ) and after 3 days of vehicle control (C) or LEE011 treatment (T). Drug response was calculated following the formula: Percentage Growth=100 × (T -T 0 )/(C -T 0 ). GI 50s were determined using sigmoidal dose-response (variable slope) curve fitting with Prism 5 software (GraphPad Software).
Cell Cycle Analysis by Flow Cytometry
Cells were exposed to inhibitors or 0.1% DMSO for 24 hr and harvested. After BrdU solution (10 mg/ml, 0.2 ml/mouse) was injected intraperitoneally 16 hours after the last dose of study drug or control. After 2 additional hours, mice were sacrificed and tumors were fixed in 10% formalin for immunohistochemical analysis or snap frozen for immunoblot analysis.
F-FDG-PET Functional Imaging Study
Matched cohorts of mice with LP6 tumors (300 mm 3 average) were randomly assigned to treatment with LEE011 (250 mg/kg) or vehicle control by oral gavage for three daily doses. Before randomization (T 0 ) and after 3 days of therapy (T 3 ), mice were evaluated by 18 F-fluorodeoxyglucose (FDG)-PET imaging (26) . Each mouse was fasted overnight before imaging and then was administered ~400 uCi
In vivo Efficacy Studies
Mice bearing LPS3 tumor xenografts (>2 mm in diameter and with volumes <100 mm 3 ) were randomized into statistically identical cohorts (6 mice/group), 
Statistical Analysis
Comparisons between groups were made using the two-tailed unpaired t-test.
Differences in means ± SEM with P < 0.05 were considered statistically significant.
Results
RB is Highly Expressed and Strongly Phosphorylated in Human Liposarcoma Cells
We determined CDK4 copy number in the 6 liposarcoma cell lines and the (Fig. 1B) .
We then examined the expression and phosphorylation level of RB as well as the status of other G 1 -S transition regulatory proteins in liposarcoma cells. As shown in Fig. 1B , RB was highly expressed and strongly phosphorylated at the CDK4/6-specific sites Ser780 and Ser807/811 (5) in liposarcoma cells in comparison to normal preadipocytes and adipocytes. Cyclin D1, p15, and p16
were expressed in all of the lipsosarcoma cells lines. CDK6 and Cyclin D2 were only detectable in a subset. These data demonstrate increased CDK4 and RB expression/activity in human liposarcoma cells.
CDK4 Knockdown Inhibits RB phosphorylation and Cell Growth in Liposarcoma Cells
To explore the role of CDK4 in regulation of RB phosphorylation and cell growth, we applied CDK4 siRNAs to LP6 liposarcoma cells and investigated their biological effects. As shown in Fig. 2A , the expression of CDK4 was dramatically decreased by CDK4 siRNAs. CDK4 knockdown resulted in a decrease in RB phosphorylation at the CDK4-specific sites Ser807/811 compared to controls ( Fig.   2A) . Moreover, growth in CDK4 siRNA transfected cells was completely blocked at 24 hr after transfection (Fig. 2B ). These results demonstrate that CDK4 is a Fig. S1 ) (25, 27) . In order to demonstrate its impact on tumor cells in vitro, we examined the effects of LEE011 in liposarcoma cells. LEE011
reduced RB phosphorylation at Ser780 and Ser807/811 in both a concentrationand time-dependent manner with complete inhibition at 3.33 μM (Fig. 3A and B, Supplementary Fig. S2 ). Correspondingly, 0.04-3.33 μM LEE011 decreased LP6 cell growth in a concentration-dependent manner, with sustained growth arrest following 24 hrs of treatment of 1.11 and 3.33 μM LEE011 (Fig. 3C and D) . Cell cycle analysis demonstrated cell cycle arrest at G 0 /G 1 and a decreased proportion of cells in S phase following 24 hr of exposure to LEE011 (Fig. 3E) .
The growth inhibitory potential of LEE011 was examined in five additional liposarcoma cell lines, and similar effects were observed in each ( Fig. 3D and   3F ). LEE011 inhibited cell growth in a concentration-dependent manner with GI 50 value of 0.13-0.24 μM (Fig. 3D) and complete inhibition at 3.33 μM, and dramatically decreased the proportion of cells in S phase (Fig. 3F ). These data demonstrate the ability for LEE011 to induce cell cycle arrest and inhibit cell growth in a variety of liposarcoma cell lines. 
LEE011 Inhibited Liposarcoma Cell Cycle Progression in a RB-
Dependent Manner
To determine the specificity of the inhibitory effects of LEE011 on cell cycle progression, we transfected cells with two independent siRNA constructs to RB and then examined the effects of LEE011 on the RB-depleted liposarcoma cells.
As shown in Fig. 4A and 4B, the observed induction of cell cycle arrest by LEE011 were dramatically abrogated in LP6 cells transfected with RB siRNA, in comparison to cells transfected with control siRNA or without siRNA. Therefore, RB is a key mediator of LEE011-induced cell cycle arrest and diminished cell growth in liposarcoma cells.
LEE011 Reduces RB Phosphorylation, BrdU Incorporation and Tumor
FDG Uptake in vivo
In order to demonstrate the impact of LEE011 on tumor behavior in vivo, we employed a xenograft model of liposarcoma cell line LP6 and further investigated the effects of LEE011 treatment on RB phosphorylation and cell proliferation. As shown by immunoblot and immunohistochemistry staining, following treatment with 3 daily doses of LEE011 (250 mg/kg/d), RB phosphorylation at Ser780 was dramatically reduced and RB protein shifted to its hypophosphorylated form ( Fig.   5A and B) . In addition, in vivo BrdU incorporation into tumors was significantly decreased (Fig. 5B) , indicative of reduced cell proliferation. We attempted to determine the in vivo effects on cellular proliferation using 3'-deoxy-3' 
LEE011 Inhibits Tumor Growth in vivo
To determine whether the observed biological effects of LEE011 treatment with vehicle control (Fig. 5E ). In contrast, the LPS3 primary liposarcoma xenograft continued to respond over the treatment period. Daily oral treatment with LEE011 (250 mg/kg) resulted in dramatic and durable tumor regression of the HSAX2655 primary liposarcoma xenografts, reaching 90% after 80 days of continuous treatment (Fig. 5G) . No significant weight loss of the mice was observed in the HSAX2655-carrying mice treated with LEE011 ( Supplementary   Fig. S3C ). We continued to monitor animals for tumor regrowth after suspension of drug treatment. Two out of 12 mice did not have palpable tumors at study termination on day 206 (91 days post-treatment cessation) and were considered complete regression. Tumors regrew in the remaining animals with varying sensitivity to retreatment with LEE011 (data not shown).
Cell Cycle Re-Entry Following Continuous Chronic CDK4/6 Inhibition in vitro
To further determine the possible causes of LP6 cell line xenograft tumor growth in the setting of prolonged LEE011 administration in contrast to the effects seen with short-term dosing, we examined the phosphorylation status of RB and the cell cycle dynamics. Chronic continuous exposure to LEE011 led to gradual recovery of RB hyperphosphorylation at the CDK4/6-specific sites S780 and S807/811 and release from cell cycle arrest after 4, 7, or 17 days (Fig. 6A) .
Concomitant with these changes, increases in cyclins D1, D2, and D3 expression were observed (Fig. 6B) , which may reflect a compensatory feedback mechanism driving cell cycle progression. The appearance of RB hyperphosphorylation and escape from cell cycle arrest were completely reversible: following a 3 day washout period from LEE011, repeat exposure to drug again resulted in suppression of RB phosphorylation and induction of G 0 /G 1 arrest (Fig. 6C) . Cyclin D2 expression similarly reverted to normal levels following drug washout but was re-induced in the presence of LEE011 (Fig. 6D) . These data suggest a dynamic mechanism that may be induced with chronic exposure and which permits escape from cell cycle arrest independent from presumed genetic selection of treatment-resistant subclones.
Discussion
In this report, we define the critical role of CDK4 overexpression and activity 
control treatment arms should be included (30) .
Additionally, our findings suggest that chronic treatment with a CDK4/6 inhibitor can lead to gradual recovery of RB hyperphosphorylation at the CDK4/6-specific sites S780 and S807/811 and re-entry into the cell cycle in one liposarcoma model. The breakthrough of cell cycle arrest does not appear to be due to selection of subclones of LP6 cells that are resistant to LEE011 on the basis of genetic alterations. Instead, removal of LEE011 led to rapid reestablishment of sensitivity to drug, suggesting a dynamic feedback mechanism that may support some level of cell cycle re-entry in this model, although the durable tumor control seen in the LPS3 and HSAX2655 xenografts indicates that this may not be a universal effect. The Phase II study of PD0332991 in liposarcoma used a 14 day on/7 day off dosing schedule, selected on the basis of determination of the maximum tolerated dose in a Phase I study (31) . Our observations suggest that this intermittent schedule may have been a fortuitous study design that enhanced anti-tumor activity by avoiding this potential feedback mechanism, although further exploration of dosing schedules with correlative pharmacodynamic studies will be essential to maximize RB hypophosphorylation, cell cycle arrest, and anti-tumor activity.
Compensatory upregulation of cyclin D1, D2, and D3 expression was also 
